MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Leucine-rich repeat kinase 2(LRRK2)"

  • 2023 International Congress

    Genetic profile of early-onset Parkinson’s Disease patients at a movement disorders center in Brazil

    M. Costa, A. Pessoa-Neto, F. Sarmento, G. Lima, C. Silva, L. Barcelos, P. Aguiar, S. Azevedo, V. Borges, H. Ferraz (São Paulo, Brazil)

    Objective: This study aimed to identify the genetic landscape of early-onset Parkinson’s Disease (EOPD) in a cohort from a referral center in Brazil. Background: Parkinson’s…
  • 2023 International Congress

    monogenic parkinsonism in latin america: systematic review and meta-analysis

    P. Saffie-Awad, D. Texeira, P. Chana-Cuevas, A. Schumacher-Schuh (Santiago, Chile)

    Objective: This study aims to assess the frequency, distribution and the minimum prevalence of monogenic Parkinsonism in Latin America (LA) Background: The prevalence of monogenic…
  • 2023 International Congress

    Oculomotor changes in the premotor stage of LRRK2- G2019S associated Parkinson’s disease.

    M. Rivera Sánchez, C. Lage Martínez, A. Sánchez Rodríguez, M. Sierra Peña, I. González Aramburu, L. Manrique Arregui, MV. Sánchez Peláez, C. García Cena, A. Calvo Córdoba, J. Madera Fernández, J. Martín Arroyo, J. Infante Ceberio (Santander, Spain)

    Objective: To analyse oculomotor differences among idiopathic PD patients (iPD), LRRK2-G2019S PD patients (LRRK2-G2019S PD), asymptomatic carriers of LRRK2-G2019S mutation (AsG2019S), and controls, evaluated by…
  • 2023 International Congress

    LRRK2 G2019S promotes astrocytic inflammatory response induced by oligomeric α-synuclein through NF-κB pathway

    JY. Liu, KJ. He, JB. Zhang, F. Wang, CF. Liu (Suzhou, China)

    Objective: Analyzing the mechanism of inflammatory response induced by oligomeric α-synuclein (O-αS) in LRRK2 G2019S mutation astrocytes to provide new targets and ideas for the…
  • 2023 International Congress

    Development of potent, orally bioavailable, and highly selective LRRK2 PROTAC® degrader molecules as potential disease modifying therapeutics for Parkinson’s disease

    K. Kelly, J. Meredith, L. Kimmel, S. Sparks, A. Desantis, D. Bryce, R. Wilson, J. Corradi, S. Keenan, G. Cadelina, J. Pizzano, A. Cacace (New Haven, USA)

    Objective: Report on the pharmacological characteristics of small molecule PROteolysis TArgeting Chimera (PROTAC) molecules designed to induce degradation of leucine rich repeat kinase 2 (LRRK2)…
  • 2023 International Congress

    monogenic parkinson´s disease in a chilean cohort

    P. Saffie-Awad, D. Texeira, A. Schumacher-Schuh, T. Leal, M. Inca-Martinez, I. Mata, P. Chana-Cuevas (Santiago, Chile)

    Objective: To describe the minimum prevalence and distribution of monogenic forms of PD in a chilean cohort Background: About 3–5% of Parkinson’s disease (PD) patients…
  • 2023 International Congress

    Caveats regarding a family with PD and LRRK2 mutations

    P. Ferreira, A. Ferreira, D. Fitas, S. Moreira, M. Calejo (Senhora da Hora, Portugal)

    Objective: To describe and discuss genetic considerations regarding a kindred with PD cases with similar clinical characteristics, some with identified mutations in the LRRK2 gene…
  • 2023 International Congress

    Caffeine Intake Interacts with Gene Variants in Parkinson’s disease

    E. Tan, Y. Ong, X. Deng, H. Li, D. Heng, K. Narasimhalu, L. Chan, P. Kumar, W. Au, P. Ratnagopal, L. Tan (Singapore, Singapore)

    Objective: We investigate interactions of caffeine intake with PD risk variants and determine PD risk estimates in caffeine-drinkers carrying these variants. Background: Caffeine intake reduces…
  • 2023 International Congress

    Assessment of variation in α-synuclein seed amplification assay results in the PPMI cohort: Association with hyposmia

    A. Siderowf, L. Concha-Marambio, D. Lafontant, R. Alcalay, L. Chahine, T. Faroud, D. Galasko, K. Kieburt, K. Merchant, B. Mollenhauer, K. Poston, J. Seibyl, C. Tanner, T. Simuni, D. Weintraub, A. Videnovic, S. Choi, C. Caspell-Garcia, C. Coffey, M. Frasier, L. Oliveira, S. Hutten, T. Sherer, C. Soto, K. Marek (Philadelphia, USA)

    Objective: To understand molecular heterogeneity among Parkinson’s disease (PD) patients, and controls based on α-synuclein seed amplification assay (SAA) results. Background: α-synuclein seed amplification assay…
  • 2023 International Congress

    Glucocerebrosidase (GCase) activator, Ambroxol, reduces alpha-synuclein serine-129 phosphorylation and oligomers in mutant LRRK2 R1441G mouse brains

    Z. Choi, E. Chang, H. Liu, S. Zhang, Y. Ruan, K. Leung, S. Pang, M. Kung, D. Ramsden, S. Ho, P. Ho (Hong Kong, Hong Kong)

    Objective: To explore whether inducing brain GCase activity by Ambroxol™ (ABX; a brain-penetrant GCase activator) can reduce a-synuclein (αSyn) serine-129 phosphorylation and oligomer accumulation in…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley